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Resumo 
 A fase (pré-) pré-analítica engloba todos os procedimentos antes do início 
dos testes laboratoriais. Esta etapa do processo é responsável pela maioria 
dos erros laboratoriais, uma vez que os procedimentos relacionados 
envolvem vários tipos de profissionais que trabalham fora do laboratório, 
portanto sem supervisão direta pelo gestor do laboratório. Portanto, é 
fundamental organizar e gerenciar corretamente o pessoal e os 
procedimentos relacionados à fase (pré-) pré-analítica. A presente tese está 
focada na prevenção dos erros laboratoriais e na otimização do 
gerenciamento da fase pré-análtica. A atividade de pesquisa e os dados sobre 
os quais a presente tese se baseia, envolveu vinte estudos (Artigos Originais) 
e uma revisão não-sistemática. Com base nos principais argumentos 
tratados, esta tese será descrita em três capítulos principais. O primeiro 
refere-se à preparação do paciente para análises laboratoriais clínicas no que 
diz respeito ao tempo de jejum. O segundo envolve o procedimento para a 
coleta de espécime diagnóstico por punção venosa de acordo com: 
desempenho de flebotomista, impacto de estase venosa na função de 
plaquetas, contaminação por EDTA e mistura de tubos primários. 
Finalmente, o terceiro capítulo enfoca a verificação de dispositivos de 
diagnóstico in vitro usados diariamente na fase (pré-) pré-analítica. Esta tese 
pode ser uma ferramenta de gerenciamento da fase (pré-) pré-analítica para 
evitar erros de laboratório, com o conceito de que resultados laboratoriais de 
espécimes diagnostico inapropriados são inconsistentes e não permitem o 
tratamento adequado nem o monitoramento do paciente. 
Palavras-chave: Coleta de amostras de sangue; Técnicas de laboratório 
clínico; Segurança do paciente; Controle de qualidade; Gestão de qualidade 
total 
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Abstract
The (pre)pre-analytical phase encompasses all the procedures before the 
start of laboratory testing. This step of the whole testing process is responsible 
for the majority of the laboratory errors, since the related procedures involve 
many sorts of non-laboratory prfessionals working outside the laboratory 
setting, thus without direct supervision by the laboratory staff. Therefore, 
it is fundamental to correctly organize and manage both personnel and 
procedures regarding (pre)pre-analytical phase. The present thesis is focused 
on the prevention of the Laboratory errors and the optimization of the pre-
analitycal phase management. The research activity and data on which the 
present thesis is based, has concerned twenty studies (Original Papers), and 
one non-systematic review. Based on the main arguments dealt with, this 
thesis will be described in three main chapters. The first one concerns the 
patient preparation for clinical laboratory analyses as regards fasting time. 
The second involves the procedure for diagnostic blood specimen collection 
by venipuncture according to: phlebotomist performace, impact of venous 
stasis on laboratory platelets, EDTA contamination, and mix of primary 
blood tubes. Finally, the third chapter focuses on the verification of in vitro 
diagnostic devices daily used on (pre-)preanalitycal phase. This thesis could 
be a (pre)pre-analytical management-tool to prevent laboratory errors, with 
the concept that laboratory results from inappropriate blood specimens are 
inconsistent and do not allow proper treatment nor monitoring of the patient.
i
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Words-keys: Blood specimen collection; Clinical laboratory techniques; Patient 
safety; Quality control; Total quality management.
Abbreviations Used
ACU automatic centrifuge unit
ADP adenosine diphosphate 
ADPtest IVD test for evaluation of platelet aggregation from Roche
ADP HStest IVD test for evaluation of platelet aggregation from Roche
ALB albumin 
ALP alkaline phosphatase
ALT alanine aminotranspherase
AMYL Amylase
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aPTT activated partial thromboplastin time
ASPI IVD test for evaluation of platelet aggregation from Roche
AST Aspartate aminotransferase
AT antithrombin III
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BD Becton, Dickinson and Company
BMI body mass index
BUN blood urea nitrogen
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CI confidence interval
CK creatine kinase
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CLSI Clinical and Laboratory Standard Institute
COL total cholesterol
COLtest IVD test for evaluation of platelet aggregation from Roche
CRE Creatinine
CRP C-reactive protein 
CVa analytical coefficient of variability
DBil direct bilirubin
DICQ National System of Accreditation from the Brazilian Society 
of Clinical Analyses
DSI desirable specification for imprecision
EDTA Ethylenediaminetetraacetic acid
EFLM European Federation of Clinical Chemistry and Laboratory 
Medicine
Eos Eosinophils
ESR erythrocyte sedimentation rate
Fe Iron
FIB Fibrinogen
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GBO Greiner Bio One
GGT g-glutamyltransferase
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LDH lactate dehydrogenase
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MPV mean platelet volume
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NEU neutrophils
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NY New York
OPB output buffer
P phosphate
PC protein C
PDW platelet distribution width
PLT platelets
PS protein S
PT prothrombin time
PTH parathormon
PTS pneumatic tube transport system
RBC red blood cells
RDW RBC distribution width
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RISTO H IVD test for evaluation of platelet aggregation from Roche
RISTO L IVD test for evaluation of platelet aggregation from Roche
SD standard deviation
TG triglycerides
TBil total bilirrubin
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TSH thyroid-stimulating hormone
UA uric acid
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WBC white blood cells
WG-PRE Working Group on Preanalytical Phase
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Preface
During my PhD program I have dealt with the (pre)pre-analytical issues 
both at University of Verona (Italy), and at Federal University of Parana 
(Brazil). The work group consists of Prof. Gian Cesare Guidi, and Prof. Geraldo 
Picheth, as advisors; and Prof. Giuseppe Lippi, Prof. Gian Luca Salvagno, Prof. 
Martina Montagnana, and Prof. Fabiane Rego, as collaborators. They helped 
me to identify the sources of error to guarantee the patient safety. I am very 
lucky because I am a young scientist and this very important work group has 
opened the doors to me. With this work group I learned, worked, and helped 
to improve the patient safety. If laboratories are vital, young scientist are 
essential to study new sources of laboratory errors thus ensuring the patient 
safety in order to improve the outcomes of the clinical laboratory.
v
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1General introduction
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2With the objective to guarantee patient safety, clinical laboratories 
are continuously improving their quality management system through 
certification and accreditation. Laboratory certification (i.e., by the ISO 
9001:2008 standard) aims to assess conformity to a specific documented 
system without verifying the technical competence, whereas accreditation 
(i.e., by ISO 15189:2012 standard) is a process aimed at providing an 
independent appraisal and recognition — by expert laboratory professionals 
— of the specific competence of testing 1, 2. Only a small number of laboratories 
worldwide are accredited 3, and some clinical directors prefer certification to 
the accreditation process when the laboratories are located inside a hospital. 
Nevertheless, the laboratory accreditation process is the best way to guarantee 
patient safety in laboratory diagnostics 4.
All laboratory tests are performed in a process – meaning a sequence 
of activities that each laboratory orderly and correctly performs in order 
to transform a given input into the desired output – that starts outside 
the laboratory with physician prescription and ends with delivery of 
laboratory report 5. The laboratory activity is virtually partitioned into three 
phases, collectively referred as the notable “brain-to-brain” loop concept: 
(pre-)pre-analytical, analytical, and (post-)post-analytical phases 6. 
The (pre-)pre-analytical phase encompasses all the procedures before 
the start of the laboratory analysis, and is responsible for the majority of the 
laboratory errors 7-9. Presently, (pre-)pre-analytical phase is formally known 
as the dark side of the moon 10 because so many best practices that exist in 
this field are mostly ignored or neglected by healthcare players. Since, almost 
70% of medical decisions depend on the results of laboratory analysis 11, 12, best 
laboratory practices should be followed in order to both prevent errors and 
guarantee patient safety.
Medical errors that jeopardize patient safety have attracted a great deal of 
public attention, especially when the situation demands the review of a large 
numbers of patient records, or a recall of patient laboratory test results, as an 
Italian case that recalled ~ 3,500 patients for parathormon (PTH) laboratory 
test 4. It is already known that 40% of diagnostic error are linked with results 
from diagnostic services such as laboratory assays, or imaging (radiology) 8, 13.
The present thesis is focused on the prevention of the Laboratory errors 
and the optimization of the pre-analitycal phase management. A systematic 
approach is a process used to determine the viability of a procedure based 
on the experiential application of clearly defined and repeatable steps with 
an evaluation of the outcomes. Moreover, the goal of a systematic approach 
is to identify the most efficient means to generate consistent, optimum 
results. The research activity and data on which the present thesis is based 
involved twenty studies (Original Papers), and one non-systematic review 
referred by their Roman numerals in the text. For exposition purposes, this 
thesis will be described in three main chapters. The first one concerns the 
patient preparation for clinical laboratory analyses as regards fasting time. 
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3The second involves the procedure for diagnostic blood specimen collection 
by venipuncture according to: phlebotomist performace, impact of venous 
stasis on laboratory platelets, EDTA contamination, and mix of primary 
blood tubes. Finally, the third chapter focuses on the verifi cation of in vitro 
diagnostic devices daily used on (pre-)preanalitycal phase (Figure 1).
Figure 1. Prevention of the Laboratory errors, and the 
optimization of the pre-analitycal phase management
The twenty studies above were summarized in a non-systematic review 
(Paper XXI).
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6General aspects due to methods
Diagnostic blood samples collected were processed following both the 
Clinical and Laboratory Standard Institute (CLSI) H18-A4 and the CLSI 
H21-A5 standards (Papers I, II, VI-XIX). Briefly, serum tubes were left 
upright at room temperature (20 °C, more than 30 min, and less than 2 h; 
standardized by study) to allow complete blood clotting before centrifugation; 
whereas plasma samples (sodium citrate, or lithium heparin) were promptly 
centrifuged. Details regarding evacuated tubes used, centrifuge force, and 
time of centrifugation are shown on Table 1.
Table 1. Information regarding evacuated tubes used, centrifuge 
force, and time of centrifugation due to brand specifications’
Tubes Centrifugation
Papers
Brand
Volume
(mL)
Additive g force
Time
(min)
Terumo
3.5
52.5 USP U of lithium heparin 
and gel separator
1200 10 I, X, XX
3.6
0.4 buffered sodium citrate (9NC) 
0.109 mol/L: 3.2 W/V%
1500 15 II, IX, X
3.5 clot activator and gel separator 1500 10 IX
BD
2.7 0.109 M buffered sodium citrate 1500 10 VII
6.0 102 I.U. of lithium-heparin 1300 10 VIII
5.0
clot activator and acrylic gel 
separator (SST II)
1500 10 XI
GBO 10.0 plan tube without additive 2000 10 II
After centrifugation, serum-samples were separated in aliquots. 
Because shortening of activated partial thromboplastin time (aPTT) 
in thawed plasma-samples may ensue, due to residual platelet debris in 
the thawed plasma-samples, a re-centrifugation was done and the platelet 
poor plasma (PPP) samples were then separed in aliquots. All aliquots from 
each study (Original Paper) were stored and kept frozen at -70 ºC until 
measurement. To assay the biomarkers in a single analytical run, all aliquots 
frozen at -70 °C from each study (Original Paper), were thawed in water bath at 
37 °C at the same time; and incubated at room temperature for 1 h. Afterwards 
the samples were handled as fresh ones.
Information from laboratory instrumentations used, and tests performed 
by each study (Original Paper) are shown Table 2. Moreover, the statistical 
tests to assess differences between either samples or procedures are shown in 
Table 3.
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9Chapter 1
Patient preparation:
fasting time
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Overview
The CLSI H3-A6 standard (presently renamed to CLSI GP41-A6) contains 
specific information regarding patient posture during blood collection by 
venipuncture, stating that “specimens should be drawn with the patient 
seated comfortably in an appropriate chair or lying down” 14. The World 
Health Organization (WHO) guidelines on drawing blood contain a different 
indication, as follows: “make the patient comfortable in a supine position (if 
possible)” 15. Consequently, healthcare professionals often assume that these 
two postural positions – either supine or sitting – could be interchangeable 
and that the shift from one posture to the other may not generate significant 
bias on laboratory testing. It is noteworthy that inpatients’ blood samples can 
be drawn at different moments and postures, e.g., in sitting position during the 
day, and in supine position during the night. On the other hand, outpatients 
(i.e., patients attending for blood collection sites) usually do not maintain a 
definite and/or stable position before venipuncture. Consequently, samples 
are frequently drawn from subjects who indifferently walked or remained 
standing for long time, or remained seated for short time – e.g., seated less 
than three minutes at phlebotomy room – before blood collection.
Lippi et al. demonstrated that postural change during venous blood 
collection impacts on coagulation tests, and is a major source of bias in routine 
clinical chemistry determinations 16, 17. Briefly, the venous pressure in the lower 
parts of the body increases after a prolonged standing position, thus generating 
an enhancement of capillary pressure which ultimately leads to ultrafiltration 
of plasma in the interstitial space. Accordingly, larger and non-diffusible 
biomarkers remain entrapped within the blood vessels, whereas smaller and 
filterable elements migrate along with water into the interstitial space 18. 
Hence to these evidences, patient posture during venous blood sampling must 
be uniformed to a reference position, either sitting or supine. Irrespective of 
the chosen criterion, a recommendation should be given that a 15–20 min 
minimum period of resting in reference position should be observed before 
collecting diagnostic blood samples 16, 17. From an organizational perspective, 
the resting period (15-20 min) could seriously impact on the workflow at blood 
collection sites – but this can be obviated by appropriately organizing and/
or scheduling the flow of the patients. Contradicting the above evidences, the 
meaningless bias observed by comparing Troponin T (TnT) values in supine 
and standing positions also suggests that it may be unnecessary to allow the 
patient rest for 15-20 min in sitting or supine position, before venipuncture 
upon admission to the emergency room, thus saving valuable time for diagnosis 
or rule out of acute myocardial infarction by TnT 19.
Regarding fasting time, an important framework for the harmonization 
of definitions for fasting requirements for laboratory tests was published 
by the Working Group on Preanalytical Phase (WG-PRE) of the European 
Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 20, this 
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document highlighted that: i) specimens for all blood tests should be drawn 
from 7 to 9 am; ii) fasting time for all blood tests should be 12 h; and iii) “no 
sample is better than a bad sample” should always be the leading principle for 
laboratory professionals.
Since the degree of bias due to non-fasting state depends on many different 
mechanisms – rate of food absortion, patient metabolism and type of food 
– 21 experiments were planned aiming to evaluate whether a light meal 
(i.e. breakfast) could jeopardize laboratory tests. These experiments were 
published in Papers I and II.
Methods 
The study population consisted of 17 healthy volunteers (8 women and 9 
men; mean age ± standard deviation: 29 ± 4 years), who were recruited among 
the laboratory personnel (Papers I and II). A single expert phlebotomist 
carried out the collection of diagnostic blood specimens. All volunteers were 
maintained seated for 15 min prior to phlebotomy in order to eliminate 
possible interferences of blood distribution due to different postures 16, 17. 
After this interval, a vein was located on the forearm by using a subcutaneous 
tissue transilluminator device (Venoscópio IV plus; Duan do Brasil, Brazil) 
for preventing venous stasis interference due to tourniquet application (see 
Chaper 2) 22-24. All blood samples (Table 1) were collected using a 20 gauge 
straight needle (Terumo Europe NV, Leuven, Belgium); to eliminate any 
possible interference due to either the contact phase or tissue factor, about 2 
mL of blood were preliminarily collected in a discard tube without additive 
(Vacuette®; Greiner Bio-One GmbH, Kremsmünster, Austria). The first blood 
sample was collected between 8:00 and 8:30 a.m., after an overnight fast. 
Immediately after blood collection, the volunteers consumed a light meal 
(breakfast), containing standardized amounts of carbohydrates, protein, 
and lipids. The meal was based on commercial food purchased at a shop to 
represent a usual breakfast. Each volunteer ate one slice of cheese, one yogurt, 
two slices of bread, one chocolate snack, and one fruit juice, as previously 
described by Lippi et al. 25. The exact composition of the meal is shown in Table 
4. Subsequent blood samples were collected at 1, 2, and 4 h after the end of the 
meal. 
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Table 4. Nutritional composition of the light meal
Nutritional composition
Slice of
cheese Yorgut
Slice of 
bread
Chocolat 
snack
Fruit 
juice Total
Number
(overall weight)
1
(25 g)
1
(125 g)
2
(46.8 g)
1
(20.7 g)
1
(200g) 417.6g
Kcal 64 134 126 105 134 563
KJ 266 562 532 438 572 2370
Protein (g) 4.4 4.1 4.2 1.1 0.8 14.6
Carbohydrate(g) 0.8 19.4 22 12.7 32 86.9
Sugar (g) 0.8 N/A 3 10 N/A 13.8
Total lipids (g) 4.6 4.4 2.4 5.5 0 16.9
Saturated lipids (g) 3.1 N/A 0.8 3.7 0 7.6
Fibre (g) 0 N/A 0.9 0.2 2 3.1
Sodium (g) 0.3 N/A 0.286 0.02 0 0.606
Calcium (g) 0.133 0.131 N/A N/A N/A 0.264
Vitamin C (g) N/A N/A N/A N/A 0.024 0.024
Kcal, kilocalorie; KJ, kilojoules; N/A, not available 
This table was previously published by Annals of Laboratory Medicine (ISSN 2234-3814)
and Blood Transfusion (ISSN 1723-2007)
Routine clinical biochemistry (Paper I), and coagulation (Paper II) tests 
were performed in duplicate, according to the manufacturers’ specifications, 
and using proprietary reagents. Both instruments (cobas 6000, and ACL 
TOP 700) were calibrated against appropriate proprietary reference standard 
material, and verified with the use of proprietary quality controls. Results 
of laboratory tests assayed from blood specimens collected before- and 
after-meal were compared. Details due to statistical tests applied, instrument used 
to assay biomarkers, and panel of tests evaluated are shown in Tables 2 and 3.
Results and Discussion
The breakfast with 14.4 g of protein (Table 4) increased significantly the 
abumin after 4 h (Figure 2-A); whereas, after 2 h of a light meal, serum levels 
of total bilirubin were significantly decreased as compared to the fasting state 
(Figure 2-B). Phisiologically, feeding stimulates albumin synthesis and this 
event might improve the storage of essential amino acids 26-29. Moreover, a 
fasting state increases hepatic uptake of non-esterified fatty acids and interferes 
with the hepatic clearance of bilirubin, thus contributing to unconjugated 
hyperbilirubinemia of fasting 30. Furthermore, insulin secretion after a meal 
induces significant changes in ions 31-35 daily measured at clinical laboratories 
(Figure 2 -C,-D,-E and -F). Regarding coagulation testing, a significantly 
higher % activity of AT was observed at 1 h, and 4 h after the ingestion of the 
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light meal as compared to baseline specimen [113 (104-117) and 111 (107-120) 
vs. 109 (102-118), respectively; P = 0.029 and P = 0.016]. Two hours after 
the ingestion of the meal, aPTT was found significantly lower than baseline 
samples [32.0 (29.9-34.8) vs. 34.1 (32.2-35.2), respectively; P = 0.041].
Figura 2. Continued
A
C
E
B
D
F
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Figure 2. Observed bias for some common laboratory parameters 
in healthy volunteers after breakfast
Hours after breakfast (x-axis) are plotted against bias values (y-axis). Solid line – bias. 
Dashed lines --- acceptable criteria based on desirable specification for imprecision 
(DSI) derived from biologic variation 36. Solid symbols (•) indicate statistically 
significance difference (P<0.05) when compared with baseline. All interferograms 
were constructed from results previously published on Papers I and II.
Dasheets from Instrumentation Laboratory reagents notify that ACL TOP 
Family System (Instrumentation Laboratory, Milan, Italy) are not affected by 
triglycerides up to: 11.3 mmol/L for both aPTT and PT, 9.9 mmol/L for FIB, 
26.0 mmol/L for AT, 10.1 mmol/L for PC, and 17.0 mmol/L for PS. However, 
the Figure 2 -G, -H, -I and -J had shown that the influence of lipemia was 
seriously underestimated, meaning that the measured bias at declared 
triglycerides concentration could be higher than reported by the manufacturer 
for aPTT, PT, AT and PC. Actually, the concentrations of triglycerides in 
samples tested were lower than 2.0 mmol/L (Paper II). Moreover, Nikolac 
et al. properly proposed that manufacturers should use evidence based quality 
specifications for assessing the allowable biases, instead of arbitrary limits 37.
Based on the evidences described above, I suggest laboratory quality 
managers to standardize the fasting time at 12 h for all blood tests; since fasting 
time at 4 h as tested was not enough to elimininate the variability caused 
by lipemia. Moreover, this kind of standardization could prevent possible 
laboratory variability that was not evaluated by this study (i.e., more caloric 
food intake as lunch or dinner) and unpredictable analytical bias (Papers I 
G
I
H
J
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and II). Indeed, if fasting time is avoided – for complete blood count, albumin, 
bilirubin, phosphate, calcium, magnesium, and potassium – more risks than 
benefits can derive for patients 21. However, in particular situations it is not 
possible to draw a blood specimen under optimal conditions (i.e., fasting 12 
h), since outpatients attending to emergency room often are in a postprandial 
state – period immediately after the meal – due to singular eating habits, and 
easy access to food (specially in developed countries) 20, 21. Besides, patients at 
afternoon consultation with general practitioner commonly are in after meal 
time too (e.g., fasting 4 h) – Figure 3 summarizes variability on laboratory 
tests owing to food intake 4 h before blood sample collection. In this case, a 
screening question might be asked to patients in order to both reduce bias and 
assist interpretation of results, particularly for patients admitted to emergency 
department, i.e., “What time was your last food intake?”. This information 
could be taken into account for interpretation of results, and during patient 
follow-up at emergency department.
Figure 3. Variability on laboratory tests due to food intake
4 h before blood collection by venipuncture
Variability is expressed as difference (bias, %) from 4 h fasting (during day) 
compared to the 12 h fasting (overnight). This figure was constructed from results 
previously published by Paper I, and Lippi et al. 27
• bias higher than desirable specification derived from biologic variation
• bias lower than desirable specification derived from biologic variation
K, potassium; Phos, phosphate; Alb, albumin; Ca, calcium; Mg, magnesium; Hb, 
haemoglobin; RBC, red blood cells; Lympho, lymphocytes; TB, total bilirubin; Eos, 
eosinophils.
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Chapter 2
Diagnostic blood specimen collection
by venipuncture
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Overview
Diagnostic blood samples collected by phlebotomy are the most common 
type of biological specimens drawn and sent to clinical laboratory facilities 
for being analyzed, thus supporting caring physicians in patient diagnosis, 
follow-up and/or therapeutic monitoring. Moreover, both diagnosis, 
management and treatment of patients can be compromised by poor quality 
of phlebotomy 38. Furthermore, phlebotomy is the most important activity in 
the extra-analytical phase 39. However, procedures involving phlebotomy are 
poorly studied as regards the major sources of laboratory errors 23.
Since 1977, the CLSI has recognized the need to put significant attention 
toward the pre-examination components of laboratory testing, including the 
correct collection of blood specimens by venipuncture – the detailed procedure 
is shown in Table 5 14.
Due to phlebotomy procedure both observational and experimental studies 
were performed (in this PhD thesis) aiming to: 
•	 evaluate the performance of phlebotomists, to identify the major 
sources of errors during diagnostic blood specimen collection 
(Paper III);
•	 verify the compliance with CLSI documents by clinical laboratories 
from South America, and to assess whether taught phlebotomists are 
following the exact procedure for blood collection by venipuncture 
due to CLSI H03-A6 document (Paper IV);
•	 verify if minor modification of the procedure for collection of diagnostic 
blood specimens by venipuncture from CLSI H03-A6 document is 
able to reduce the tourniquet application time (Paper V);
•	 evaluate the impact of venous stasis on platelet function assessed 
by multiple electrode aggregometry (Paper VI);
•	 assess the impact of sodium citrate- and lithium-heparin-blood 
samples contaminated with different amounts of dipotassium 
ethylenediaminetetraacetic acid (K2EDTA blood) on routine 
coagulation (Paper VII), and clinical chemistry (Paper VIII) 
laboratory tests;
•	 evaluate the effect of tubes mixing (gentle vs. vigorous) on 
diagnostic blood specimens collected in vacuum tube systems by 
venipuncture (Paper IX); and
•	 evaluate whether it is really necessary to mix the primary blood 
tubes immediately after blood collection by evacuated tube systems 
(Paper X).
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Methods
Performance of phlebotomists
The checklist (proposed in my Master Degree dissertation, Table 6) 66 was 
followed to evaluate the performance of phlebotomists during diagnostic 
blood specimen collection by venipuncture (Paper III), regarding: i) time of 
tourniquet application; ii) inappropriate requests to patients to clench their 
fist repeatedly; iii) either excessive or aggressive disinfection of the forearm 
by the phlebotomist, which can induce venous stasis; iv) the order of drawn 
of evacuated tubes during specimen collection; and v) the mix of primary 
blood tubes (with either anticoagulant or clot-activator) in conformity with 
manufacturer datasheet. Moreover, this checklist allowed to correlate source 
of laboratory errors with improper phlebotomy procedures witnessed; such 
as increased potassium concentration in the specimen due to fist clenching by 
the patient.
The phlebotomist performances were analyzed only during procedures 
involving blood collection in evacuated tubes containing additives (i.e., clot 
activator, sodium citrate, ethylenediaminetetraacetic acid [EDTA], heparin, 
or sodium fluoride). To standardize the approach, and to reduce the bias, 
the performance of each phlebotomist was evaluated when blood was being 
collected from patients with the following characteristics: between the ages of 
18 and 65 years, nonpregnant, nonobese (i.e., body mass index [BMI] < 30 kg/
m2), not undergoing chemotherapy, or catheterization, and neither afflicted 
with any apparent vascular disease. All these conditions were carefully 
excluded because they might be associated with difficulties during the 
collection of diagnostic blood specimens, which thereby might introduce bias 
into the evaluation. The performance of each phlebotomist was monitored in 5 
different venipunctures; the time of tourniquet application was measured with 
a calibrated chronometer. The time interval between tourniquet application 
and removal were recorded in seconds. Moreover, the laboratory quality 
managers were the only laboratory personnel informed about this research; 
the phlebotomists were unaware that data were being collected.
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Table 6. Checklist to assess the performance of phlebotomists 
during diagnostic blood specimen collection by venipuncture
Procedure Verification
1)   Tourniquet application time
Patient I
Patient II
Patient III
Patient IV
Patient V
_______seconds
_______seconds
_______seconds
_______seconds
_______seconds
2) Did the phlebotomist inap-
propriately request the patient to 
clench the fist repeatedly?
1 Yes (  ) 2 No (  )
3) Did the phlebotomist make 
the friction movement of the 
forearm, during the cleaning of 
the venipuncture site, to induce 
venous stasis?
1 Yes (  ) 2 No (  )
4) Did the phlebotomist use 
the correct sequence of vacuum 
tubes during blood collection?
1 Yes (  ) 2 No (  )
5) What was the sequence of 
tubes used by the phlebotomist?*
(  ) sodium citrate #
(  ) sodium fluoride #
(  ) EDTA #
(  ) clot activator and gel separator #
(  ) 
6)  Did the phlebotomist mix the 
diagnostic blood specimens?
     1 Yes (  ) 2 No (  )
* This item is evaluated only if the answer to procedure 4 was “no”.
# Enumerate the order of the sequence used. 
This table was previously published by Biochemia Medica (ISSN 1330-0962)
the phlebotomist does not have a 
standardized sequence; the tubes are 
randomly  inserted into the vacuum 
collection system.  
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Survey 
To verify the use of CLSI standards (Paper IV) in South America, a survey 
was sent by mail to 3674 laboratories, with the five questions following: 
i) Do you use standardized operating procedures in all your 
laboratory activities?
ii) If yes, what steps of your laboratory process are based on CLSI 
guidelines? #
( ) pre-analytical                ( ) analytical                ( ) post-analytical
( ) my processes are not based in CLSI guidelines 
# If you marked “my processes are not based in CLSI 
guidelines”, then specify where your procedures are based. 
If you had checked the above preanalytical option, do you 
currently employ the CLSI H03-A6 document 14 to standardize 
your procedures for blood collection by venipuncture?
iii) If yes, do your phlebotomists perform the blood collection by 
venipuncture following the exact venipuncture procedure from 
page 5 item 8 of CLSI H03-A6 document 14?
iv) If not, what did you change in this procedure? And why did 
you change this procedure? 
Phlebotomy training program
After analyzing the survey results, thirty phlebotomists from São Paulo 
state, Brazil, (previously evaluated on Paper III) were invited to be trained 
according to CLSI H03-A6 standard aiming to eliminate phlebotomy errors 
(Paper IV). These professionals had 5 (4.8-5.6) years of experience in 
diagnostic blood specimen collection by venipuncture. The above professionals 
were operational at institutions where approximately 200 blood collections 
by venipuncture are performed per work-day. Each phlebotomist was trained 
individually to perform exactly the venipuncture procedure from CLSI 
H03-A6 document – page 5 item 8 14. The phlebotomy-training program was 
realized during 8 h where the importance of each step of the procedure was 
explained (Table 5). Only one external/expert auditor from DICQ 67 trained all 
phlebotomists in one month. DICQ is a National System of Accreditation from 
the Brazilian Society of Clinical Analyses. This accreditation system is based 
on ISO 15189:2007 68. After the training, all phlebotomists were monitored 
for twenty work-days to guarantee the assimilation of the correct procedures 
for the collection of diagnostic blood specimen, in conformity with the CLSI 
H03-A6 document (Table 5). Only after this period of time, the phlebotomists 
were re-evaluated, using the same checklist (Table 6) and method described 
above. Moreover, laboratory quality managers consider this period of time 
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sufficient for incorporating new procedures. 
A second training (Paper V) was executed for the same thirty phlebotomists 
(previously appraised on both Paper III and Paper IV). Each phlebotomist was 
retrained individually to perform the new venipuncture procedure proposed 
in Paper IV (Table 7). The phlebotomy-training program was delivered over 
8 h, during which the importance of each step of the updated procedure 
was clearly explained. After training, all phlebotomists were monitored and 
appraised with the same methodology, and checklist described above.
Table 7. The most important proposed changes to venipuncture 
procedure
Steps from CLSI H03-A6
Changes proposed
(Paper IV)
vi
Apply the tourniquet and select the 
venipuncture site and vein
Put on gloves
vii Put on gloves Cleanse the venipuncture site
viii
Cleanse the venipuncture site and 
allow to dry
Request the patient to just close his/her 
hand (never request the patient to “pump”)
ix
Perform venipuncture; once blood 
flow begins, request the patient to 
open his/her hand
Apply the tourniquet and select the 
venipuncture site and vein
x
Fill tubes using the correct order 
of draw
Perform venipuncture; once blood flow 
begins, request the patient to open his/
her hand
Also release and remove the tourniquet
xi Release and remove the tourniquet Fill tubes using the correct order of draw
The steps identification (Roman numbers) from the original CLSI H03-A6 standard 
(presently replaced by the CLSI GP41-A6 document) 14. 
This table was previously published by Biochemia Medica (ISSN 1330-0962)
Impact of venous stasis on platelet function
The study population consisted of 20 healthy volunteers (11 women 
and 9 men; mean age ± SD: 29 ± 4 years), who were recruited among our 
laboratory personnel (i.e., 74 individuals). The inclusion criteria were 
based on the anamnestic exclusion of blood coagulation disorders, platelets 
dysfunction, diabetes, dyslipidemias, thalassemia syndromes and other 
hemoglobinopathies; as regards women, that they had regular menstrual 
cycles and were not using hormonal contraceptives (Paper VI). None of 
the volunteers took any medication. BMI was less than 30.0 kg/m2 in all 
volunteers. The collection of diagnostic blood specimen was performed by a 
single, expert phlebotomist, following the previously published protocols 22-24. 
Briefly, all volunteers after 12 h fasting were maintained seated for 15 min to 
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eliminate interferences due to posture 16, 17. After this time frame, 6 mL of blood 
was collected by venipuncture with a 20 G straight needle (Terumo Europe, 
Leuven, Belgium) directly into two 3 mL Hirudin blood tubes for Multiplate 
analysis following two different procedures: 
Procedure 1 (no stasis) – a radial vein was localized on the right forearm 
by a subcutaneous tissue transilluminator device (Venoscopio IV plus, Duan 
do Brasil, Sao Paulo, Brazil) without tourniquet, to prevent any interference 
from venous stasis 22-24; 
Procedure 2 (stasis) – an antecubital vein was localized on the left forearm 
by tourniquet application during 60 s prior to venipuncture. 
To eliminate any potential interference due to either the contact phase or 
the tissue factor, a first 2 mL discard tube was drawn from each volunteer for 
both procedures. All samples were processed for the assessment of platelet 
function by multiple electrode aggregometry (MEA) after collection (<15 min) 
on the same Multiplate instrument equipped with electronic pipette, and 
using proprietary software by Multiplate. The instrument had been previously 
calibrated by the manufacturer (during production). The calibration 
maintenance was contextually verified with the use of proprietary quality 
controls (liquid control set, ref 06675999 190, Roche Diagnostics GmbH). 
Principle: in the Multiplate Test Cell, activated platelets adhere to, and 
aggregate on, the sensor wires. This leads to an increased resistance between 
the sensor wires, which is continuously recorded and expressed via the 
area under the curve in arbitrary units (i.e., AU*min or U). Approximately 
8 AU correspond to 1 Ω69. The panel of tests included ADP-test (without 
prostaglandin E1), ADP HS-test (with prostaglandin E1), ASPI-test, 
COL-test, RISTO H-test (high concentration, 0.77 mg/mL), RISTO L-test (low 
concentration, 0.20 mg/mL), and TRAP-test (Table 8). 
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Table 8. Multiplate® portfolio to assay platelet function by MEA
Tests Description
ADP
ADP induced platelet activation sensitive to 
clopidogrel, prasugrel and other ADP receptor 
antagonists
ASPI
Cyclooxygenase dependent aggregation (using 
arachidonic acid) sensitive to Aspirin®, NSAIDs 
and other inhibitors of platelet cyclooxygenase
COL Collagen induced aggregation
RISTO
Von Willebrand factor (vWF) and  glycoprotein Ib 
(GpIb) dependent aggregation using ristocetin
TRAP
Platelet stimulation via the thrombin receptor using 
a protease-activated receptor 1 agonist (TRAP-6), 
sensitive to IIb/IIIa receptor antagonists
Prostaglandin
E1 reagent
For the assessment of ADPtest HS (high 
sensitivity). For the assessment of positive 
(i.e. abnormal) controls of the ADPtest
Ethylenediaminetetraacetic acid (EDTA) 
contamination and order of drawn
Fifteen healthy volunteers, were enrolled among the laboratory 
personnel to assess the impact of sodium citrate- and lithium 
heparin-blood samples contaminated with different amounts of dipotassium 
ethylenediaminetetraacetic acid (K2EDTA blood) on routine coagulation 
(Paper VII), and clinical chemistry (Paper VIII) laboratory tests. The blood 
was drawn at rest following the procedure proposed at Paper IV (Table 7), 
after overnight fast, by an experienced phlebotomist. The tubes were filled up 
to their nominal volume (Table 1), and all phases of sample collection were 
standardized. 
Five citrate tubes of each subject were pooled to obtain 10.8 mL of sodium 
citrate-anticoagulated blood (Paper VII), and two lithium-heparin tubes of each 
subject were pooled to obtain 12 mL of heparinised blood (Paper VIII), which 
were then divided in 5 aliquots of 2 mL each. The whole blood of the K2EDTA 
tube was then added in scalar amounts to the autologous blood aliquots, to 
obtain different degrees of K2EDTA blood contamination (Table 9).
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Table 9. Volumes used to obtain different degrees of K2EDTA 
blood volume contamination
                                                                                              Aliquots
Samples A B C D E
Sodium citrate (Paper VII) 2 mL 2 mL 2 mL 2 mL 2 mL
Litium heparin (Paper VIII) 2 mL 2 mL 2 mL 2 mL 2 mL
K2EDTA* -
0.1 mL
(5%)
0.3 mL
(13%)
0.8 mL
(29%)
1.5 mL
(43%)
Concentration (mg/dL)* 0.00 0.09 0.24 0.51 0.77
*percentage values regard the proportionality of autologous blood (volume/volume). 
EDTA concentration was estimated from the preceding EDTA-containing tube. It was 
predicted taking into account a mass concentration of 1.8 mg of K2EDTA per 1 mL of 
blood, as declared by BD®.
The aliquots were then mixed by gentle inversion and centrifuged at room 
temperature. All parameters were measured in one single analytical run 
according to manufacturer’s specifications (Table 2); and using proprietary 
reagents with the same lot number. The analyzers were also previously 
calibrated against appropriate proprietary reference standard material and 
verified by third-party internal quality control. 
Mixing of primary blood tubes
Blood samples were collected for routine coagulation, immunochemistry, 
and hematological testing to evaluate both the effect of tubes mix – gentle vs. 
vigorous – (from 100 volunteers, Paper IX), and whether it is really necessary 
to mix the primary blood tubes immediately after blood collection (from 300 
volunteers, Paper X) by evacuated tube system.
Paper IX – Immediately after the venipuncture all evacuated tubes (one 
from each additive type) were processed through two different procedures: 
Procedure 1 — Gold Standard 63, 65: all diagnostic blood specimens collected 
in tubes with K2EDTA or sodium-citrate were gently inverted five times, as 
recommended by the manufacturer 70, 71. Specimens collected in evacuated 
tubes with clot activator and gel separator (serum tubes) were gently inverted 
ten times, since the manufacturer recommends to gently invert each tube 
several times to maximize the contact between blood and silica (clot activator) 
after blood collection 72.
Procedure 2 — Vigorous mixing: immediately after collection all blood 
specimens were shaken up vigorously during 3–5 seconds, independently on 
the additive type inside the evacuated tubes. 
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A
Paper X – All evacuated tubes were processed due to three diff erent 
procedures: 
Procedure 1 – Gold Standard: all specimens were mixed gently and 
carefully by inverting fi ve times as recommended, then properly centrifuged 
(Figure 4A);
Procedure 2 – Rest time: all specimens remained 5 min in the upright 
position, followed by gentle careful mixing by inverting fi ve times, then 
properly centrifuged (Figure 4-B);
Procedure 3 – No mix: all specimens were left in upright position without 
mixing afterwards, then properly centrifuged (Figure 4-C).
Details from both evacuated tubes, and instruments used to assay 
biomarkers for Papers IX and X were shown in Tables 1 and 2.
Figure 4. Continued
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Figure 4. Processing of evacuated tubes
Color of stopper means additives as follow: blue, sodium-citrate; green, 
lithium-heparin; and purple, EDTA.
B
C
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Results and Discussion
The answers from 2781 laboratories (Paper IV) were received throughout 
the study period (i.e., 60 days), that is 76% of the total previously predicted 
(Figure 5-A). The results of the survey are shown in Figure 5-B. Briefly, the 
survey shows that CLSI documents are widely used in South America since 
2622 (94%) from 2781 laboratories appear compliant with these documents 
to standardize their procedures.
Figure 5. Representativeness of CLSI documents in South America
Figure 5-A: Geographic distribution of evaluated laboratories by survey.
All evaluated countries are shown textured. The absolute number represents the 
group of laboratories evaluated by countries. 
This figure was previously published by Biochemia Medica (ISSN 1330-0962)
A
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The major nonconformities observed during phlebotomies are summarized 
in Table 9. The fi rst phlebotomists’ evaluation (Paper III) had shown that the 
overall rate of errors was over 60%. There were no signifi cant diff erences 
observed between public and private laboratories except for adequate mix 
of primary blood tubes, for which private laboratories had fewer errors 
(P = 0.04).
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Phlebotomists after training according to CLSI H03-A6 (Paper IV) 
completely eliminated several nonconformities, including: i) incorrect friction 
on the forearm during the cleaning of the venipuncture site (e.g., this procedure 
induce venous stasis, making easy the vein location); ii) incorrect order of draw; 
and iii) inadequate mix of primary blood tubes (i.e., with either anticoagulants, 
or clot activator). Moreover, all phlebotomists inappropriately requested the 
patient to clench the fist repeatedly (i.e., more than twice) (Table 10). 
Regarding tourniquet time (Figure 6), the overall means were 84.4 s (Paper 
III), 118 s (Paper IV), and 30 s (Paper V). Persistently, private laboratories 
applied the tourniquet for significantly shorter time than public laboratories: 
69.9 s vs. 98.9 s, P < .001 (Paper III); 87 s vs. 148 s, P < 0.001 (Paper IV); and 
28 s vs. 32, P = 0.002 (Paper V). 
Figure 6. Assessment of tourniquet time application during 
diagnostic blood specimen collection by venipuncture
Tourniquet application time in seconds from 30 different phlebotomists. The 
performance of phlebotomists due to tourniquet application time is shown in 
three different colors: in blue phlebotomists without specific train (Paper III), 
in red phlebotomists after being trained on CLSI H03-A6 procedure (Paper IV), 
and in green the phlebotomists’ performance after training on new procedure that 
improved the steps sequence from CLSI H03-A6 document (Paper V). Tourniquet 
time were classified: higher than 60 s, as nonconformity; between 30 s and 60 s, as 
acceptable; and less than 30 s, as desirable.
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These evidences mirror that the venipuncture procedure from CLSI 
H03-A6 document page 5 item 8 14 induces venous stasis due to tourniquet 
application time > than 60 s. Briefly, venous stasis by tourniquet application 
(> than 60 s) promotes the outflow of water, diffusible ions and low molecular 
weight substances from the blood vessels, thus increasing the concentration 
of biomarkers at the venipuncture site (Figure 7) 73. This source of laboratory 
variability has been extensively investigated in the past decade 74-76. Sixty 
seconds of venous stasis are per se able to significantly modify (i.e., P < 0.05) 
both routine clinical biochemistry, haematology, and coagulation tests 22-24. 
Moreover, tourniquet application during 60 s generates bias higher than 
sought by quality specifications derived from biological variation for: i) total 
protein (2.8% vs. 1.2%, respectively, P= 0.001); ii) albumin (2.4% vs. 1.3%, 
respectively, P= 0.001); iii) potassium (6.5% vs. 1.8%, respectively, P=0.001), 
and iv) calcium (1.3% vs. 0.8%, respectively, P=0.001) 24.
Figure 7. Venous stasis due to tourniquet application 
A1. Schematic upper limb without tourniquet application; A2. Schematic blood 
vessels environment at physiological condition. B1. Schematic upper limb after 
tourniquet application; B2. Schematic blood vessels over tourniquet application; 
B3. Schematic blood vessels at venous stasis condition due to tourniquet application 
by more than one minute. 
This figure was previously published by Scandinavian  Journal  of Clinical  and  
Laboratory  Investigation (ISSN 0036-5513)
A device able to minimize the variability induced by venous stasis was 
validated (i.e., Venoscopio from Duan®, a transilluminator device) 22-24. The 
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transilluminator device is essentially based on cold near infrared light-emitting 
diodes (LEDs), whose light is absorbed by intra-erythrocyte haemoglobin 
flowing along the veins. Interestingly, Weiss and Goldman had proposed the 
transillumination for mapping veins to be cannulated prior to ambulatory 
phlebotomy, because this practice would allow a more accurate visualization 
of the vein course 77. Presently IVD companies that provide evacuated tubes 
and needles, also provide transilluminator systems. Becton, Dickinson and 
Company is exclusive partner of AccuVein (Huntington, NY) in 30 countries 
78, whereas Greiner Bio-One GmbH (Kremsmünster, Austria) is the official 
distributor of VeinViewer (Christie Medical Holdings, Inc., Memphis, 
Tennessee) in Brazil and Italy 79. Since transilluminator is not broadly used in 
phlebotomy services in South America (mainly due to the incremental cost), 
a critical evaluation of international adherence to the phlebotomy procedure 
described in the CLSI H03-A6 standard was carried out (Paper IV), showing 
that the minor modifications proposed to the standard were effective to 
decrease tourniquet application time to less than 35 s and 30 s in public- and 
private-laboratories, respectively (Paper V), thus substantially contributing 
to reducing the bias generated by venous stasis. Presently, the proposed 
new procedure for collection of diagnostic blood specimens by venipuncture 
(Table 7) should be strongly suggested for use by all quality laboratory 
managers and/or phlebotomy coordinators in their services, in order to avoid 
preanalytical errors due to venous stasis. Moreover, Bölenius et al. 80 used the 
hemolysis index (HI) to assess the efficiency of a large-scale 2 h educational 
intervention. The authors concluded that the training had only minor effects 
on blood collection practices. This large-scale 2 h education intervention was 
supported by laboratory instructors from the Country Council of northern 
Sweden focusing on rehearsal and implementation of both the national 
and local venous blood specimen collection guidelines, that is similar to 
international standards (CLSI H03-A6 document) 80. This kind of training 
program should instead be strongly recommended and performed worldwide. 
Furthermore, previous investigations had shown that educational program, 
and technological interventions for phlebotomists are relevant and promote 
decrease of error rates – consequently resulting in quality improvement 81-84. 
Maybe Bölenius et al. 80 found only minor effects because the procedure from 
CLSI H03-A6 document increase the tourniquet application time.
As regards the impact of venous stasis on MEA (Paper VI), a difference 
was observed between the responses of platelets collected under- and 
without-stasis using both ADP (a weak platelet agonist) 85 and low-dose of 
ristocetin (Table 11). Briefly, ristocetin is an antibiotic known to induce 
thrombocytopenia and platelet agglutination. In the presence of ristocetin 
platelets bind to von Willebrand’s factor (VWF) through glycoprotein Ib (GPIb) 
receptors. In vitro, ristocetin forms complexes with VWF molecules, which 
bind to GPIb and trigger platelet activation and aggregation. Reduced or lack 
of agglutination in the presence of ristocetin – by RISTO-test for Multiplate 
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– is attributed to absence or reduction of VWF, or to lack or deficit of platelet 
GPIb receptors, such as in Bernard–Soulier syndrome 86. RISTO-test is a 
sensitive assay for diagnosing both Bernard–Soulier syndrome and severe von 
Willebrand’s disease. Moreover, Table 10 shows that platelet agregation due 
to RISTO L-test is significantly reduced by approximately 15% after 1 min of 
venous stasis. A possible explanation of such a subtle, although significant, 
reduction might be attributable to local flow disruption caused by venous 
stasis (Figure 7) on one hand, and the consequently enhanced proteolysis by 
ADAMTS13 on the largest and more reactive VWF molecules on the other 87.
Table 11. Impact of venous stasis on Multiplat® e tests 
Test
Procedure
Mean % 
difference
Bland–Altman
P value
Stasis No stasis
Mean 
bias
95 % CI
ADP
62.5
[48.2–75.0]
67.0
[53.8–78.2]
-7.2 3.75 -5.15–12.6 0.040
ADP HS
61.0
[34.2–72.0]
61.5
[40.5–73.8]
-0.8 0.38 -14.5–15.3 0.888
ASPI
83.5
[74.0–93.0]
86.5
[73.8–89.5]
-3.6 -0.38 -16.0–15.3 0.889
COL
72.0
[60.0–88.8]
74.0
[60.5–82.2]
-2.8 0.75 -14.8–16.4 0.944
RISTO L
9.50
[3.88–18.4]
12.2
[6.12–19.8]
-28.4 1.75 -1.07–4.57 0.015
RISTO H
130
[122–154]
128
[116–162]
1.5 2.31 -20.9–25.5 0.853
TRAP
92.5
[75.0–95.0]
91.5
[80.5–106.5]
1.1 6.12 -7.51–19.8 0.031
This table was previously published by Blood Coagulation &  Fibrinolysis  (ISSN  0957-5235)
ADP-test and ADP HS-test on Multiplate has been developed for evaluating 
platelet activation via platelet ADP receptors. The ADP stored in the dense 
granules of platelets is released during activation, a phenomenon accompanied 
by shape change. The released ADP further activates adhered platelets in 
addition to activating local free circulating platelets by binding to purinergic 
receptors – P2Y1 and P2Y12 on platelet membranes. When platelets are 
activated, the individual components of the glycoprotein IIb/IIIa receptors 
on platelet membrane physically alter their conformation, thus producing 
the high-affinity fibrinogen-binding site glycoprotein IIb/IIIa. Fibrinogen, 
both freely circulating and released from alpha granules, subsequently binds 
to the glycoprotein IIb/IIIa receptors forming platelet-to-platelet bridges 
resulting in platelet aggregation. Thus, the effect of 1 min venous stasis on 
ADP-test (without-prostaglandin E1) is consistent with a significant reduction 
Livro_Gabriel_finalizado_INGLES_REDUZIDA.indd   35 05/04/2017   11:01:19
36
of platelet sensitivity to ADP agonist. Significantly, platelets collected without 
stasis were statistically more responsive to ADP and low-dose of ristocetin 
than platelets collected after stasis (ADP-test and RISTOL-test, Table 11). 
Moreover, no differences between stasis vs. no stasis in platelet responses 
to ADP were apparent if prostaglandin E1 was added to activated platelets 
(ADP HS-test). Furthermore, the two groups of platelets (stasis, and no stasis) 
were less responsive to ADP in the presence of prostaglandin E1 than in its 
absence (Table 11), as was expected. A likely reason for the dampening effects 
of prostaglandin E1 on platelet responses to ADP is the well known ability 
of prostaglandin E1 to dampen platelet responses to all platelet agonists 88. 
Consequently – the results suggest that – tourniquet use by 60 s during blood 
specimens collection could induce inappropriate changes in antiplatelet/
anticoagulant therapy, as a consequence of biased aggregation data. Moreover, 
the recommendation from CLSI GP41-A6 document (formerly CLSI H03-A6) 
14 regarding tourniquet time application – anyhow not to be extended over 60 
s – is not enough to assure the quality of aggregation data by Multiplate, and 
thus patient safety. As such, the tourniquet should be avoided when assessing 
platelet function by MEA.
EDTA salt (e.g. K2- or K3-EDTA) is an anticoagulant widely used, especially 
for hematological testing or to stabilize the whole blood for the plasma 
assessment of both unstable and fragile molecules (i.e., cytokines, peptides and 
cardiac biomarkers) 89. The current blood collection guidelines incorporate the 
so-called ‘order of drawn’ originally proposed by Calan and Cooper 61 to reduce 
the risk of cross-contamination of additives (i.e., EDTA) from a previously 
filled tube (Figure 8). The suggested sequence entails 1st blood culture bottle 
or tube without additive; 2nd sodium citrate tube; 3rd serum tube with or 
without clot activator and with or without gel separator; 4th heparin tube with 
or without gel separator and/or dedicated-syringe with heparin; 5th EDTA 
tube with or without gel separator; and 6th glycolytic inhibitor tube 14.
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BA C 
Figure 8. Theoretical principle of EDTA carryover during blood 
collection using evacuated tube system
A. Schematic multi-sample blood collection needle connected to holder placed on 
venipuncture site at upper limb. Briefly the multi-sample blood collection needle 
show two different serial needles: one “external” to insert into the vein and other 
on the opposite, covered by rubber to fill the evacuated tubes. The rubber sheath 
allows multiple tubes of blood to be collected and covers the needle in between tube 
changes, so blood lacks contact with holder.
B. Schematic blood collection by venipuncture at begin – external needle is into 
median cubical vein and EDTA evacuated tube was inserted into the holder. The 
EDTA salt (spray-dried) on the internal-walls of the evacuated tube is both dissolving 
(solubilization process), mixing and stabilizing by the blood collected, due to blood 
turbulence generated by the standardized negative pressure inside evacuated tubes.
C. Schematic blood collection by venipuncture at the end – EDTA evacuated tube was 
full filled till the nominal volume, consequently the internal needle directly contacted 
the blood collected with EDTA salt due to evacuated tube orientation (e.g., with the 
stopper placed on a lower plane than the bottom, between 15° and 30°), thus exposing 
the following tube in the sequence of draw to a theoretical risk of additive carryover. 
This figure was previously published by Scandinavian  Journal  of Clinical  and  
Laboratory  Investigation (ISSN 0036-5513)
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Experimentally K2EDTA blood volume contamination had shown that the 
free carboxylic acid form of EDTA – after K2EDTA dissociation – strongly 
chelates divalent metal ion as Ca++ and Mg++ on lithium heparin blood tubes 
(impacting on clinical chemistry determination, Paper VIII). Moreover, 
K2EDTA blood volume contamination on sodium citrate blood tubes may 
hence jeopardize coagulation testing (Paper VII). Statistically and clinically 
significant prolongation was observed for both aPTT and PT between 29% 
and 43% of K2EDTA contamination, whereas the decrease of fibrinogen 
values became statistically and clinically significant at 43% of K₂EDTA 
contamination. Moreover, significant variations starting from 5% of K2EDTA 
contamination were observed for: calcium, chloride, iron, LD, magnesium 
(all decreased) and potassium (increased). The variation of phosphate and 
sodium (both increased) were significant after 13% and 29% of K2EDTA 
contamination, respectively (Figure 9). Furthermore, the presence of K2EDTA 
or K3EDTA in either serum or plasma specimens may mask true cases of 
hypokalaemia or hypercalcaemia, whereas true cases of hypokalaemia may 
be misjudged as significant hyperkalaemias 90. Cornes et al. performed a 
multicentre observational study and showed that spurious hyperkalaemia due 
to EDTA contamination is relatively frequent. This evidence led the authors to 
suggest an education program to: i) correct blood collection technique; and ii) 
prevent EDTA sample contamination 91. Afterwards, the same team of authors 
evaluated a series of blood collections – blood were drawn by evacuated 
tube system, sequentially into a serum tube, followed by a EDTA tube, and 
followed by another serum tube – where potassium EDTA contamination 
was not evidenced 92. Similar data were published in a subsequent study, 
demonstrating that serum tubes collected after either a K2EDTA or a sodium 
citrate blood tube do not show a clinically meaningful interference on 
potassium or calcium assessment 93. At variance with this conclusion, a case 
report, where a dedicated-syringe for blood gas analyses was contaminated 
by EDTA evacuated tube and lead to inaccurate results of both potassium 
and calcium was published 94. Possibly the EDTA carryover during blood 
collection could be correlated with either phlebotomy practice or evacuated 
tubes producers’, since each trademark provided different results on routine 
hematological testing (i.e., complete blood count, see Chapter 3 as regards 
Papers XVI and XVII). Since evidences regarding EDTA contamination were 
rather consistently different, the need to strictly follow the order of drawn to 
guarantee patient safety is questioned. As a reliable approach to prevent that 
unreliable data are generated, the measurement of EDTA in hyperkalaemic, 
hypocalcaemic and hypomagnesaemic samples may be advisable in order to 
exclude EDTA salt contamination. Indeed, the assessment of EDTA in serum is 
inexpensive and can be easily implemented in the vast majority of automated 
analyzers 95.
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Figure 9. Continued
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Figure 9. Effect of different extents of samples with K2EDTA 
blood volume contamination on potassium, activated partial 
thromboplastin time (aPTT), prothrombin time (PT), phosphate, 
sodium, calcium, magnesium, chloride, lactate dehydrogenase 
(LDH), iron, and fibrinogen. 
The percentage bias is shown as mean and 95% confidence interval (95% CI). 
The dotted lines delimit the desirable quality specifications for bias. 
This figure was previously published by International  Journal of  Laboratory  
Hematology  (ISSN  1751-553X) and Biochemia Medica (ISSN 1330-0962)
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The gentle inversion to mix primary blood tubes is currently advocated by 
the CLSI 14. In theory: i) when blood tubes are mixed by gentle inversion, the risk 
of formation of micro clots, clots or fibrin filaments is limited; and ii) a vigorous 
mixing (or shaking) promotes either erythrocyte injury or spurious hemolysis 14. 
Experimentally these theories were demystified. Since, no significant differences 
(P > 0.05) were detected between the mix procedures 1 and 2 – gold standard 
vs. vigorous mix – for routine coagulation, immunochemistry, or hematology 
testing (Paper IX). Therefore, either vigorous- or gentle-mix tubes immediately 
after blood collection have similar effect on laboratory results. Surprisingly, 
all samples vigorously mixed before centrifugation had shown only a visual 
alteration (presence of foam on the top, Figure 10 -A2.2, -B2.2, C2.2); and all 
serum tubes from vigorous mix procedure had shown a “blood ring” on the tube 
top after stopper removal (Figure 10-B3.2).    
Figure 10. Three types of evacuated tubes with additive in the 
two different mix procedures
A. Sodium citrate evacuated tube. B. Serum evacuated tube with clot activator and gel 
separator. C. K2EDTA evacuated tube. For each evacuated tube type (A–C), 1. Empty 
tube. 2. Tubes before centrifugation, respectively with gentle inversion/gold standard 
(2.1) and vigorously (2.2) mix (both manually). 3. Tubes after centrifugation respectively 
with inversion/gold standard (3.1) and vigorously (3.2) mix , both manually too.
This figure was previously published by Clinical Biochemistry (ISSN 0009-9120)
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As regards the mixing of primary blood tubes immediately after blood 
collection by evacuated tube systems; it appears to be unnecessary (Paper 
X). Since, neither fibrin filaments, microclots nor clots were observed in 
samples not mixed, avoidance of mixing primary evacuated tubes does not 
carry a substantial risk of clotting. Moreover, significant statistical differences 
were found for: i) RBC and hematocrit when Procedure 1 (gold standard) was 
compared with Procedure 2 (rest time); ii) ALT and ESR when Procedure 1 
(gold standard) was compared with Procedure 3 (no mix); and iii) RBC, HCT 
and HI when Procedure 2 (rest time) was compared with Procedure 3 (no mix). 
Surprisingly, clinically significant differences were found only for Na when 
Procedure 1 (gold standard) was compared with Procedure 2 (rest time), and 
Procedure 2 (rest time) was compared with Procedure 3 (no mix), Table 12. 
Moreover, these results confirmed the outcomes published by Parenmark and 
Landberg 96, Table 13. Tube mixing by gentle inversion or through horizontal 
mixing tray immediately after blood collection may increase the value of the 
hemolysis index compared with no mixing. Moreover, the blood turbulence 
inside evacuated tubes (due to negative pressure) is itself sufficient to provide 
solubilization, mixing and stabilization of additives in blood.
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Chapter 3
Verification of in vitro
diagnostic devices
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Overview
The processes of qualification, validation, verification, and nonconformity 
management are essential in accredited laboratories 2 (Table 14). However, 
seldom the verification process is regarded as an issue in the preanalytical 
management. Indeed, the laboratory staff may start to use new in vitro 
diagnostic devices – e.g., a brand/kind of evacuated tubes, new medical 
devices, or transport systems – without (or prior to) any verification. The 
ISO 15189:2012 document contains clear indication that “all necessary 
improvements and potential sources of nonconformities, either technical 
or concerning the quality management system, shall be identified and all 
laboratory process shall be validated” 2.
Table 14. Terms and definitions from ISO 9000:2005 standard 97 
Terms Definition 
Requirement The need or expectation, which is explicitly 
declared or implied, to be achieved
Non-conformity Non fulfillment of a requirement
Qualification The process to demonstrate the ability to fulfill 
specified requirements. 
Verification The confirmation, that specified requirements 
have been fulfilled. 
Validation The confirmation, that the specified requirements 
for a specific intended use or application have been 
fulfilled. 
Presently, diagnostic products can be divided into either of two major 
categories: i) in vitro diagnostic (IVD) devices, such as laboratory instruments, 
reagents, assays, and blood collection tubes; ii) medical devices, such as 
specimen collection devices (needles and sets), whilst each one has its own 
technical characteristics devised for specific use 98. Although most blood 
tubes are traded and available worldwide, their use should require previous 
verification by laboratory managers. 
An IVD device called Buzzy® (MMJ Labs LLC, Atlanta GA USA) has 
been proposed for phlebotomy, which combines a cooling ice pack and a 
vibrating motor in order to relieve the venipuncture pain 99-101. Since, Buzzy® 
is worldwide distributed, also delivered directly to patients 102, laboratories are 
using Buzzy® without previously verification.
In order to save resources (human, equipments, and financial), many 
health services have centralized a large number of the main analytical 
activities in the so-called core-laboratories: where blood specimens are 
delivered from peripheral collections sites. This implicitly means that a large 
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number of samples are convoyed from one facility to another. Moreover the 
core-laboratory may be settled inside a hospital where the various clinical 
departments – i.e., intensive care unit, emergency department, cardiology, 
and others – can be considered as peripheral collection sites. Alternatively, 
the main laboratory can be located externally to hospitals, thus providing 
activity to collection sites that are strategically located for collecting samples 
from large geographical areas (e.g., private laboratories servicing regional 
healthcare). 
Inside a hospital, the sample transport is frequently done by pneumatic 
tube transport systems, able to deliver specimens from departments to 
core-laboratory, thus reducing the overall turnaround time 103-105. However, 
this kind of specimen transportation is frequently performed without previous 
verification, as regards the potential source of variability. Furthermore, plasma 
samples are frequently collected in gel tubes, centrifuged, and transported in 
safety bags, since the gel should virtually create a barrier between plasma, 
and blood cellular components. Recent evidence has been provided that 
centrifuged heparin gel tubes should be maintained in closure-up position 
to avoid errors in clinical diagnosis, especially in longitudinal comparison 
of patient’s data using aspartate aminotransferase, lactate dehydrogenase or 
potassium determination, as biomarkers 106. Serum tubes with gel separator 
should be preferably used in standard protocols of clinical research, when 
there is a high risk that the maintenance in closure-up position during the 
transport after centrifugation cannot be ensured 106.
At the begin of the 21st century, robotic automation is poised to revolutionize 
laboratory practices 107. The final goal of automation and consolidation in 
clinical laboratories is to ensure reliable information to assist physicians in 
patient management and improving clinical outcomes 108-113. Presently, most 
technological devices are increasingly devised to perform repetitive tasks so 
far pertaining to human operators, with advantages in terms of accuracy, 
speed, convenience, and cost. Moreover, there is a long history of quality 
requirements in clinical laboratory, yet the concern has mainly regarded the 
analytical phase of this process 114. Owing to substantial advances in technology, 
laboratory automation, and analytical quality, there is mounting evidence that 
further quality improvements should be targeted to extra-analytical activities 
of the total testing process (i.e., automation for pre-analytical process) 39, 115-118.
Experimental studies were performed regarding laboratory verification (in 
this PhD thesis) aiming:
•	 to evaluate the impact of Buzzy® use during diagnostic blood specimen 
collection by venipuncture for both routine immunochemistry 
(Paper XI) and hematological testing (Paper XII);
•	 to verify if the same kind of dedicated-syringes for blood gas, and 
evacuated tubes – i.e., with- sodium citrate, clot activator, lithium heparin, 
and EDTA – from different brands could be a source of variability for 
laboratory testing (Papers: XIII, XIV, XV, XVI, XVII, and XVIII);
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•	 to evaluate the impact of a pneumatic tube transport system for 
routine hematological testing (Paper XIX); and
•	 to evaluate whether automation for the pre-analytical phase 
improves data quality (Paper XX).
Methods
Verification of Buzzy® impact on laboratory tests 
To evaluate the impact of Buzzy® use during diagnostic blood specimen 
collection  by venipuncture on immunochemistry (Paper XI) and hematology 
(Paper XII), blood samples were drawn from 100 volunteers by a single, 
expert phlebotomist. A vein was located in the left forearm without applying 
a tourniquet. This was done by a subcutaneous tissue transilluminator device 
(Venoscópio IV plus, Duan do Brasil, Sao Paulo, Brazil), thus avoiding the 
venous stasis. Blood samples were collected with a 20G straight needle 
directly into evacuated tubes: one 5 mL tube with clot activator and acrylic gel 
separator, and one 4 mL tube with 5.9 mg of K2EDTA (Table 14). Nearly 2 mL 
of blood were preliminarily collected into a discard tube without additive to 
exclude potential interference from contact phase activation of blood, or tissue 
factor. In sequence, external cold and vibration was established by Buzzy® on 
the right forearm – 5 cm above the venipuncture site – for 1 minute before 
venipuncture and continued until the end of blood collection by venipuncture 
with the same procedure performed in the left forearm, as described above 
(Figure 11). Results of immunochemistry (Paper XI), and hematological 
(Paper XII) tests assayed from blood specimens collected without- and 
with-Buzzy® use were compared. Details from instrument used to assay 
biomarkers are shown in Table 2.
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Figure 11. Schematic representation of Buzzy® use evaluation 
during diagnostic blood specimen collection by venipuncture
A. left forearm, blood specimens were drawn without either tourniquet or Buzzy® .
B. right forearm, tourniquet application was avoided, and blood specimens were 
drawn after Buzzy®  use during one minute 5 cm above the venipuncture site.
Verifi cation of in vitro diagnostic devices
The collection of all diagnostic blood specimens to verify evacuated tubes 
(Papers: XIII, XIV, XV, XVI, and XVII) were performed by a single, expert 
phlebotomist. All volunteers, after 12 h fasting, were maintained seated for 15 
min prior to phlebotomy. After this time interval, a vein was located on forearm 
by a subcutaneous tissue transilluminator device (Venoscópio IV plus, Duan®, 
Sao Paulo, Brazil), then blood samples were collected by venipuncture with a 
20 G straight needle directly into the appropriate IVD device (evacuated tubes) 
described in Table 15. To eliminate any potential interference due to either the 
contact phase or the tissue factor, ~2 mL of blood were preliminarily collected 
in a discard tube without additive. In order to verify blood gas syringes (Paper 
XVIII), all volunteers after 8 h fasting, were maintained seated near the blood 
gas analyzer during 15 min. A single expert nurse performed all blood specimen 
collection following the CLSI H11-A4 119 procedure. Briefl y, after puncture of 
radial artery using 21 G butterfl y, 9.6 mL of blood were drawn directly into four 
diff erent heparinized-syringes (Table 15).
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The sequence of syringes was randomized, however, syringe from Brand 2 
were always the last to be collected, to eliminate the possible contamination 
from liquid sodium heparin. Before connecting each syringe, ~1.5 mL of blood 
volume were discarded in order to replenish the butterfly extension tube and to 
wash out possible interferences due to residual heparin. All the samples were 
processed following CLSI H18-A4 65. Moreover, blood collection materials 
(i.e., IVD devices, and medical devices) were accurately standardized in these 
studies (Papers: XIII, XIV, XV, XVI, XVII, and XVIII) – syringes, butterfly, 
needle, evacuated tubes, and sodium heparin were from a single lot – and 
samples were assayed according to the manufacturer’s specifications, using 
proprietary reagents. Results of Immunochemistry (Papers XIII and XIV), 
hematological (Papers XVI and XVII), coagulation (Paper XV) tests assayed, 
and blood gas analyses (Paper XVIII) from blood specimens collected with 
different Brands of in vitro diagnostic devices were compared. Details from 
instrument used to assay biomarkers are shown in Table 2. 
Verification of pneumatic tube transport 
system for routine hematological testing
A group of 50 apparently healthy volunteers of both genders were enrolled 
to blood withdrawal after 8 h fasting. A single, expert phlebotomist performed 
the collection of all diagnostic blood specimens. All volunteers were maintained 
seated during 15 min prior to phlebotomy. After this interval, a vein was 
located on forearm by a subcutaneous tissue transilluminator device without 
tourniquet, and venipuncture with 20 G straight needles were performed: 2 mL 
of blood were preliminarily collected in an evacuated tube without additive; 
then two identical 3.0 mL evacuated tubes containing 5.9 mg of K2EDTA were 
drawn (Table 1). Samples from each volunteer were transported according to 
two parallel procedures (Paper XIX).
Transport-procedure I: Diagnostic blood specimens were kept in 
vertical, closure-up position, and hand carried by laboratory personnel in an 
appropriate biohazard container at room temperature (20 ± 1 °C) from the 
phlebotomy site to the core laboratory. The mean transport time was 7 min.
Transport-procedure II: Samples were transported by a pneumatic tube 
transport system (Op1000, Oppent S.p.A, Milan, Italy), which connects the 
phlebotomy site (outside the hospital) with the core laboratory on the hospital 
at 1st floor (point-to-point). There are neither heat nor cold sources along this 
route. The system generates a maximum speed of 3 m/s. The mean transport 
time from phlebotomy site to core laboratory was 85 s.
Paired samples (from transport procedures I and II) were analyzed at the 
same time for routine hematological testing (<15 min after blood collection), 
and erythrocyte sedimentation rate (Table 2).
Livro_Gabriel_finalizado_INGLES_REDUZIDA.indd   51 05/04/2017   11:01:21
52
Verification of laboratory automation for 
pre-analytical phase
A group of 100 adult ambulatory outpatients, 54 female and 46 male, with 
an average age of 49 years (range, 46–69 years) were enrolled as volunteers 
in this study. A single, expert phlebotomist performed the collection of all 
blood samples. All volunteers, after 12 h fasting, were maintained seated for 
15 min prior to phlebotomy. After this time interval, a vein was located on 
forearm by a subcutaneous tissue transilluminator device, without tourniquet 
placement, and 7 mL of whole blood was collected by venipuncture with a 20 
G straight needle, directly into two 3.5 mL evacuated tubes with 52.5 USP 
lithium heparin and gel separator. To eliminate any potential interference due 
to either the contact phase or tissue factor, ~2 mL of blood were preliminarily 
collected in a discard tube without additive. The lithium heparin tubes, one 
from each volunteer, were separately processed according to traditional-, and 
automated-processing (Paper XX).
Traditional Processing 65
One hundred tubes (one from each volunteer) were left in the upright 
position for 10 min at room temperature (20 °C) to allow complete in vitro 
anticoagulation before centrifugation at 1200g for 10 min at room temperature, 
on the same centrifuge Rotanta 460R (Andreas Hettich GmbH & Co. KG, 
Tuttlingen, Germany). All primary tubes processed by traditional method 
were uncapped manually and immediately placed into the cobas 6000 <c501> 
module (Roche Diagnostics GmbH, Mannheim, Germany) to assay the clinical 
chemistry tests (Table 2). 
Automated Processing
The other 100 tubes, one from each volunteer, were left in the upright 
position for 10 min at room temperature (20 °C) to allow complete in vitro 
anticoagulation. The tubes were then placed in racks suited for the following 
process into one MODULAR PRE-ANALYTICALS EVO (MPA) system (Roche 
Diagnostics GmbH, Mannheim, Germany). The MPA system includes modules 
that centrifuge, aliquot patient samples, automatically perform removal and 
insertion of container stoppers, and add barcode label (Figure 12) 120. The 
automatic centrifuge unit (ACU) is a module inside MPA used to centrifuge 
samples based on parameters (such as rotation rate and duration) defined in 
the total system manager. 
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The centrifuge is self-balancing, and a single ACU can accommodate up 
to 40 samples (8 racks) at a time. A MPA system can be configured with 
either one or two ACU modules. For this evaluation, only an ACU was used 
for centrifugation at 1200g for 10 min at room temperature. Then only one 
aliquot from each primary evacuated tube was performed by MPA system. 
Samples from the MPA system were fed directly into the same cobas 6000 
<c501> module to assay the clinical chemistry tests (Table 2), without further 
staff intervention. 
When all clinical chemistry testing was finished: i) the samples from the 
traditional processing were stored at +4 °C, as common practice in clinical 
laboratory, and as prescribed in accredited laboratories;  ii) the primary tubes 
from the automated processing (i.e., MPA) were stored inside the output buffer 
(OPB) in the same MPA system. Briefly, OPB stores racks contain the primary 
samples intended for offline processing at room controlled temperature 120. All 
samples were stored during 6 h, and the same panel of tests (Table 2) was then 
performed on the same cobas 6000 <c501> module. Results from both different 
processing procedures and different storing procedures were compared.
Results and Discussion
The new device to relieve venipuncture pain – that combines a cooling ice 
pack and a vibration motor – called Buzzy®, can be used during diagnostic 
blood specimens’ collection by venipuncture for the majority of the routine 
immunochemistry tests (Papers XI). This device shall be avoided when blood 
samples are collected for: protein, albumin, transferrin, or complete blood 
count determination, Table 16 (Papers XI and XII). Recently, the findings on 
the bias induced by this device were challenged 121. However, a strong evidence 
had shown that the combination of cold and vibration close to the venipuncture 
site generate by Buzzy® device should be considered a potential source of 
pre-analytical variability – significant decreases (i.e., P < 0.05) were observed 
for: white blood cells (WBC), neutrophils (NEU), and lymphocytes, whereas 
significant increases (i.e., P < 0.001) were observed only for red blood cells 
(RBC), haemoglobin (Hb) and haematocrit (Hct) (Paper XII). In contrast, I had 
shown that the tourniquet application during either 60, 90, 120, or 180 s caused 
significant increases on: platelets, WBC, NEU, monocytes, and eosinophils 
(i.e., P < 0.05, when compared with the parallel blood collection with 
transilluminator, Table 17) 22. The physiology disturbance on vein environment 
caused by either of variability sources – i.e., vein stasis by tourniquet application 
(Figure 7), or that due to the combination of cold and vibration close to the 
venipuncture site – during blood collection should be avoided to guarantee both 
patient safety and the best laboratory outcomes.
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The verification of in vitro diagnostic devices – evacuated tubes, and 
syringes for blood gas analysis – had shown that different brands of evacuated 
tubes provided different laboratory results, Table 18 (Papers: XIII, XIV, XV, 
XVI, XVII, and XVIII). The presumable cause for these divergences could be 
attributed to the interaction between blood and evacuated tubes components, 
e.g., surfactant(s), stopper(s), stopper-lubricant(s), separator gel(s) and 
active(s) 122. Moreover, blood gas analysis could be influenced by dedicated 
syringes produced from different manufacturers due to diverse preparations 
such as: i) presence of dry heparin inside the syringes; ii) mechanisms for 
elimination of the air bubbles from samples before mixing; iii) different 
materials of syringes and stoppers. Furthermore, the sample collection for 
blood gas analysis using common plastic syringes washed with sodium heparin 
before arterial puncture should also be avoided.
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With regard to the verification of pneumatic tube transport system (PTS) 
(Paper XIX) neither statistical nor clinical significant differences were 
observed between samples from Transport-procedure I (hand carried) and 
Transport-procedure II (PTS) for routine hematological testing, erythrocyte 
sedimentation rate, and reticulocytes (Table 19). 
Table 19. Variability in routine hematological testing from two 
different transport procedures
Tests Units
Comprehensive results
P-value
PTS Hand carrying
RBC* (1012/L) 4.90 ± 0.51 4.91 ± 0.51 0.1691
HGB* (g/L) 14.1 ± 1.86 14.1 ± 1.88 0.2521
HCT* (%) 44.8 ± 5.42 44.9 ± 5.46 0.1747
MCV*  (fL) 91.5 ± 7.13 91.5 ± 7.16 0.2752
RDW†  (%) 12.9 [12.5–14.7] 12.8 [12.6–14.6] 0.2815
WBC† (109 /L) 6.28 [5.61–9.06] 6.27 [5.54–9.09] 0.1212
NEU* (106 /L) 4.42 ± 1.85 4.34 ± 1.78 0.0308
LYMPHO† (106 /L) 1.95 [1.51–2.63] 1.95 [1.48–2.52] 0.8999
MONO* (106 /L) 0.46 ± 0.18 0.47 ± 0.20 0.8949
EOS* (106 /L) 0.21 ± 0.12 0.21 ± 0.12 0.6452
BASO†  (106 /L) 0.04 [0.03–0.07] 0.04 [0.03–0.06] 0.5494
LUC* (106 /L) 0.14 ± 0.05 0.14 ± 0.06 0.5071
PLT* (109 /L) 219 ± 45.0 218 ± 46.6 0.8548
MPV* (fL) 8.94 ± 0.66 8.92 ± 0.64 0.8813
PDW* (%)   48.7 ± 5.44 49.0 ± 5.65 0.7629
RETIC†   (109 /L) 71.4 [63.5–80.7] 68.6 [60.0–76.0] 0.0383
ESR† (mm/h) 29.5 [24.0–39.5] 30.0 [22.5–38.5] 0.3765
PTS, pneumatic tube transport system.
*Normal distribution; the values were mean± standard deviation; P-value represents the 
significance by paired Student’s t-test. †Non-normal distribution; the values were median 
(interquartile range); P-value represents the significance by Wilcoxon ranked-pairs test. 
This table was previously published by International  Journal of  Laboratory  Hematology 
(ISSN  1751-553X)
To my best knowledge this was the first study that evaluated the impact of 
PTS on erythrocyte sedimentation rate determination by TEST 1 YDL (Alifax, 
Polverara, Italy). Others five main studies have investigated the effects of PTS 
on complete blood count, and my results (Table 18) are generally comparable 
with these studies 105, 123-126. Moreover, laboratory quality managers before start 
using the PTS should evaluate important procedures such as the correct filling 
of primary blood evacuated tubes, the speed of transport, and the impact 
endured by the container on arrival. Furthermore, previous investigation 
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showed that the use of PTS for diagnostic blood transport increases the 
frequency of hemolyzed samples 127-129 and could jeopardize patient safety 
regarding the hemostasis tests, and platelet functions 130-132. However, the 
highest rates of hemolyzed samples are seen in systems with intermediate 
switching stations that accelerate and decelerate specimens 133, unlike the 
point-to-point (direct phlebotomy to core-laboratory) pneumatic tube system. 
The apparent limitation of my study (i.e., the exclusive use of a point-to-point 
PTS, Paper XIX) might instead further substantiate the outcomes of other 
studies where increased hemolysis index was observed after using PTS with 
switching stations that accelerate and decelerate specimens.
Laboratory automation and consolidation both aim to ensure consistent 
information to support physicians in patient management and improve 
clinical outcomes 108-113. Since the preanalytical phase is responsible for several 
sources of laboratory variability, the laboratory automation for this phase 
can improve both quality of sample and patient safety; provided that the 
best practices (as described in Chapter 1 and Chapter 2) are followed during 
both blood collection and specimens handling. Various types of preanalytical 
automation are able to sort primary blood tubes and perform centrifugation 
when required (e.g., to obtain plasma or serum specimens). In these 
systems the primary blood tube types are recognized by the cap color. The 
color-coding for blood collection tube closing is used as indicator to identify 
additives. Nevertheless, the present cap colors from different producers of 
blood collection tubes lack standardization, and this fact is a potential cause of 
laboratory errors 134. The MPA system effectively reduces the labor associated 
with specimen processing and decreases the number of laboratory errors that 
occur with specimen sorting, labeling, and aliquoting. This is a predictable 
advantage, if one considers that the instrument (Figure 12) does not require 
routine human manipulation. The more interesting finding is that the MPA 
system preserves the integrity of sample handling throughout the activities of 
specimen processing, Table 19 (Paper XX). Some suggestions can be advanced 
to explain these findings: i) the primary tubes are recapped and stored for 
further analyses (when needed) more rapidly in the MPA system than in the 
traditional processing; ii) when the process takes place starting after the MPA 
system, all tests are directly performed without a break on aliquoted-barcoded 
cups, whereas the primary tube remains open inside the cobas 6000 <c501> 
module (as in all brands of clinical chemistry analyzers) during the measuring 
process, using traditional processing; iii) blood tubes are manually recapped 
and stored at the end of the process, when the rack tray in the analyzer is full. 
The evidence of biases increases in COL, TG, TP, ALB, CRE, UA, ALP, AST, 
LDH, CA, FE, NA, and K, when traditional processing was compared with 
automated processing after storage, can be explained by the fact that either 
high- or low-molecular-weight analytes are affected by water evaporation in 
open tubes (Table 20). This is confirmed by previous evidence that tubes which 
remain open for a long time display significant variation in the concentration 
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of macromolecules, enzymes, and ions 135, 136. This hypothesis also supports the 
significant biases increases observed between traditional processing before 
storage and traditional processing after storage for COL, TG, TP, ALB, CRE, 
UA, AST, LDH, P, CA, MG, FE, NA, and K (Table 20). Although it might be 
provocatively concluded that the results of this verification (Table 20) may be 
considered clinically irrelevant, this would not consider the current quality 
specifications for bias, derived from biological variation 137. Obviously, the 
quality specifications derived from biological variation are considered of pivotal 
importance, and their usefulness is acknowledged in daily practice by quality 
managers of medical laboratories 36, 137-139. As such, the caring physicians, who 
are unaware of the real patient situation, might abstain from appropriate 
treatments as a consequence of biased results from traditional processing of 
diagnostic blood specimens. It is also noteworthy that the relative (percentage) 
increases of the various analytes was rather broad and heterogeneous (i.e., 
ranging from -1.9% to +15.9%) and thereby a priori unpredictable. For a 
rational explanation of the consequences of uncontrolled evaporation, it should 
be considered that in serum/plasma where the pH is about 7.4, the interfacial 
water molecules between air (which is over the interface) and liquid bulk 
(which is under the interface) are polarized with stronger hydrogen bonding 
in the surface than in the bulk. This creates water solvation and ionization 
properties that change at the interface, with a depth of about 250 nm, where 
ions and hydrophilic solutes such as proteins are generally becoming less 
soluble. Moreover, plasma proteins that are mainly in the form of anions at pH 
7.4 are progressively repelled by the evaporating surface, thus concentrating in 
the liquid bulk. During the process, the proteins more proximal to the interface 
can partially dehydrate and shrink, with conformational changes possibly 
involving chemical reactivity. Complex molecules, such as lipoproteins, are 
expected to behave according to the lipid/apoprotein ratio 140, 141. The results 
(Table 20) had shown that the MPA system can really improve the quality in 
the pre-analytical phase of laboratory testing. 
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Key concepts
In order to prevent laboratory errors and to optimize the preanalytical 
phase management it must be considered that laboratory tests influence as 
many as ~70% of medical decisions 13, thus any errors throughout the total 
testing process can jeopardize patient safety.  In this context, the accurate 
management of the preanalytical phase is the way forward to guarantee the 
best outcomes regarding the prevention of the Laboratory errors. Moreover, 
the patient preparation for clinical laboratory analyses, the procedure for 
diagnostic blood specimen collection by venipuncture, and the verification of 
in vitro diagnostic devices are essential to properly report a laboratory test. 
On the above basis, this Thesis was aimed to highlight some preanalytical 
priorities to prevent laboratory errors and to optimize the preanalytical phase 
management, as listed:
•	 Patient preparation: fasting time should be mandatory for the 
mainstream laboratory tests (Papers: I and II);
•	 Phebotomists’ performance: laboratory quality managers 
should evaluate the performance of their phlebotomists to generate 
quality indicators using a check list (Paper III); 
•	 Prevention of venous stasis: tourniquet should be applied after 
cleansing the venipuncture site; once blood flow begins tourniquet 
should be released and removed to guarantee best laboratory 
outcomes (Papers: IV and V); wherears tourniquet shall be avoided 
to evaluate platelet function by MEA (Paper VI). Moreover, either 
cold and vibration near venipuncture site to eliminate pain, should 
be avoided (Papers: XI and XII);
•	 EDTA contamination and order of tube collection: 
the assessment of EDTA in serum is inexpensive and could be 
implemented in automated analyzers. Moreover, the order of draw 
should be still followed (Papers: VII and VIII);
•	 Mixing primary blood tubes: blood turbulence inside evacuated 
tubes due to negative pressure is itself sufficient to provide 
solubilization, mixing and stabilization of additives in blood; additional 
mixing procedure could be unnecessary (Papers: IX and X);
•	 Assembly of the necessary devices for in vitro diagnostics: 
verification should be performed before local routine implementation 
of blood collection tubes, or new devices (Papers: XI-XVIII);
•	 Transport of the blood specimens: the kind of transport 
(pneumatic- vs. hand-transport) should be validated by local 
laboratory for each assay (Paper XIX);
•	 Laboratory automation for preanalytical phase: the laboratory 
automation of this phase can improve both quality of sample and patient 
safety, if the best practices (as described above) are correctly followed, 
during both blood collection and specimens handling (Paper XX).
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 General Conclusion 
This thesis could represent a (pre)pre-analytical management-tool to 
prevent laboratory errors, with the concept that laboratory results from 
inappropriate blood specimens are inconsistent and do not allow proper 
treatment nor monitoring of the patient. The most important question when 
dealing with the laboratory sources of error is not “how big is one single source 
of variability?” but, “how big could be the error if all sources of variability 
impact together over a single laboratory outcome?”. General practitioners, 
nurses, technicians, and laboratory professionals all need to operate together 
to reduce laboratory variability in each single step described above, with the 
aim to guarantee the reliability of the results and thus the safety of patients.
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